Company / CapEx per Share
Jazz Pharmaceuticals CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.97
FY2025
5-year range
$0.24 / $0.97
FY2021-FY2025
Trend
+58.5%
vs FY2024
Sector context
#13 of 192
Health Care
What the data says
Among 192 Health Care companies, Jazz Pharmaceuticals is in the top 7% for capex per share. CapEx per Share has increased for 3 consecutive years, from $0.24 in FY2022 to $0.97 in FY2025.
Based on SEC 10-K filings.
0.97 in FY2025 with a 5-year CAGR of +21.7%. Top quartile in the Health Care sector.
Improved from $0.38 to $0.97 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- +58.5%
- 5-Year CAGR
- +21.7%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 192This company $0.97 Sector average $2.46
▼
-60.7% below sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's capex per share has grown for 3 consecutive years.
- In FY2025, capex per share increased 58.5% year-over-year.
- Ranks #13 out of 192 companies in the Health Care sector.
- Lowest capex per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.97 | +58.5% |
| FY2024 | $0.61 | +61.3% |
| FY2023 | $0.38 | +55.7% |
| FY2022 | $0.24 | -65.9% |
| FY2021 | $0.71 | +96.9% |
| FY2020 | $0.36 | -27.7% |
| FY2019 | $0.50 | +205.0% |
| FY2018 | $0.16 | -66.0% |
| FY2017 | $0.48 | -18.4% |
| FY2016 | $0.59 | -0.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026